Seattle breakthrough offers Spokane boy relief from rare hunger condition
A new FDA-approved therapy is showing success in treating hypothalamic obesity caused by brain tumors and injuries.
Velocity
How fast coverage is spreading — measured hourly from article rate × source diversity. How this works →
The brief
Medical reports confirm the emergence of setmelanotide as a treatment for hypothalamic obesity resulting from brain damage. Clinical trials and individual patient outcomes indicate the medication is helping individuals manage symptoms of constant hunger.
Coverage from The ASCO Post, the limbic, and NR Times details the clinical efficacy of the drug, specifically noting reductions in BMI. Local reporting from KREM and The Spokesman-Review highlights the personal experience of a patient from Spokane who received care through a Seattle medical facility.
Observers are looking to further clinical application of the therapy following its recent FDA approval. It remains to be seen how broadly this treatment will be integrated into standard care for patients suffering from acquired hypothalamic obesity.
Synthesized by headlinez.news from the headlines below under a strict no-invention contract. ✓ fact-checked: all claims supported by sources Updated 4h ago.
Quick answers
What is the new therapy?
The therapy is called setmelanotide, which has received FDA approval for treating obesity caused by brain injury or tumors.
How does setmelanotide work?
Coverage states it is used to manage hypothalamic obesity, with clinical trials showing it can lead to a reduction in BMI.
Who is eligible for this treatment?
The FDA approval specifically pertains to patients suffering from acquired hypothalamic obesity resulting from brain tumors or brain damage.
Coverage (5)
- Setmelanotide in Patients With Acquired Hypothalamic Obesity From Brain Tumors The ASCO Post · 1d ago
- ‘Back to living life’: Spokane boy finds treatment to constant hunger caused by brain damage The Spokesman-Review · 1d ago
- Setmelanotide cuts BMI in hypothalamic obesity trial the limbic · 1d ago
- FDA approves new therapy for obesity caused by brain injury NR Times · 1d ago
- Seattle breakthrough offers Spokane boy relief from rare hunger condition KREM · 1d ago
Topics
Related trends
FDA still focused on Taylor Farms lettuce as Cyclospora source despite retracted test
The FDA continues its investigation into Taylor Farms regarding a Cyclospora outbreak despite retracting a recent test result.
Too many Britons are too fat to work
New research indicates that more than 600,000 individuals in the United Kingdom are currently unable to work due to obesity.
Alzheimer's: Real-world study confirms Leqembi therapy benefits
The FDA has authorized an at-home subcutaneous injection for Leqembi, marking a shift in treatment delivery for early-stage Alzheimer's patients.
Explosive diarrhea outbreak: Lettuce tests positive for cyclospora, FDA says
A nationwide iceberg lettuce recall across 27 states follows positive tests for the Cyclospora parasite and reported illnesses.
Pillsbury recalls 2 bread products over potential glass contamination
General Mills has issued a recall for Pillsbury bread roll products due to the risk of glass contamination.
Brain-shuttle biologics chart new paths across the blood–brain barrier
New brain-shuttle biologics are emerging as a potential mechanism to bypass the blood–brain barrier for Alzheimer’s and cancer treatment.